Literature DB >> 34284173

Novel insights on the molecular mechanism of action of the anti-angiogenic pyrazolyl-urea GeGe-3 by functional proteomics.

Elva Morretta1, Raffaella Belvedere2, Antonello Petrella3, Andrea Spallarossa4, Federica Rapetti5, Olga Bruno6, Chiara Brullo7, Maria Chiara Monti8.   

Abstract

In recent years, 5-pyrazolyl-ureas have mostly been known for their attractive poly-pharmacological outline and, in particular, ethyl 1-(2-hydroxypentyl)-5-(3-(3-(trifluoromethyl) phenyl) ureido)-1H-pyrazole-4-carboxylate (named GeGe-3) has emerged as a capable anti-angiogenic compound. This paper examines its interactome by functional proteomics using a label-free mass spectrometry based platform, coupling Drug Affinity Responsive Target Stability and targeted Limited Proteolysis-Multiple Reaction Monitoring. Calreticulin has been recognized as the GeGe-3 principal target and this evidence has been supported by immunoblotting and in silico molecular docking. Furthermore, cell studies have shown that GeGe-3 lowers cell calcium mobilization, cytoskeleton organization and focal adhesion kinase expression, thus linking its biological potential to calreticulin binding and, ultimately, shedding light on the reasonable action mechanism of this molecule as an anti-angiogenic factor.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Calcium homeostasis; Drug affinity responsive target stability; Functional proteomics; Limited proteolysis; Molecular docking; Protein–ligand interactions; Target discovery

Mesh:

Substances:

Year:  2021        PMID: 34284173     DOI: 10.1016/j.bioorg.2021.105168

Source DB:  PubMed          Journal:  Bioorg Chem        ISSN: 0045-2068            Impact factor:   5.275


  4 in total

Review 1.  The Development of FAK Inhibitors: A Five-Year Update.

Authors:  Andrea Spallarossa; Bruno Tasso; Eleonora Russo; Carla Villa; Chiara Brullo
Journal:  Int J Mol Sci       Date:  2022-06-07       Impact factor: 6.208

2.  A Proteomic Platform Unveils the Brain Glycogen Phosphorylase as a Potential Therapeutic Target for Glioblastoma Multiforme.

Authors:  Giusy Ferraro; Matteo Mozzicafreddo; Roberta Ettari; Lorenzo Corsi; Maria Chiara Monti
Journal:  Int J Mol Sci       Date:  2022-07-25       Impact factor: 6.208

3.  Drug affinity-responsive target stability unveils filamins as biological targets for artemetin, an anti-cancer flavonoid.

Authors:  Giusy Ferraro; Raffaella Belvedere; Antonello Petrella; Alessandra Tosco; Björn Stork; Stefano Salamone; Alberto Minassi; Federica Pollastro; Elva Morretta; Maria Chiara Monti
Journal:  Front Mol Biosci       Date:  2022-08-25

4.  The Pyrazolyl-Urea Gege3 Inhibits the Activity of ANXA1 in the Angiogenesis Induced by the Pancreatic Cancer Derived EVs.

Authors:  Raffaella Belvedere; Elva Morretta; Nunzia Novizio; Silvana Morello; Olga Bruno; Chiara Brullo; Antonello Petrella
Journal:  Biomolecules       Date:  2021-11-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.